Thymine Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

Several clinical trials sponsored by academic and hospital institutions, including Indiana University and Bispebjerg Hospital in collaboration with Sygehus Lillebaelt, investigate thymine-related biomolecular processes and radiation effects. Categorized under the Phase Not Applicable designation, these studies evaluate urinary DNA repair biomarkers and dermal rejuvenation techniques across conditions such as radiation-induced DNA damage, DNA adduct formation, ultraviolet injury, and pre-cancerous geriatric skin. Their recruitment statuses currently range from completed to active, not recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05277961	Active not recruiting	Ultraviolet Rays; Injury\|DNA Adduct Formation\|DNA Damage Radiation Induced\|DNA Damage	Bispebjerg Hospital\|Sygehus Lillebaelt	2022-03-01	Not Applicable
NCT02090894	Completed	Pre-cancerous Geriatric Skin	Indiana University	2011-03	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Thymine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Thymine incorporates into genomic DNA as an essential pyrimidine nucleobase, forming selective hydrogen bonds with adenine to facilitate accurate nucleic acid replication and preserve structural integrity. Upon exposure to ultraviolet radiation, adjacent thymine bases undergo photochemical dimerization to produce cyclobutane pyrimidine dimers, inducing local DNA damage that is central to evaluating tissue repair responses in ultraviolet-induced injury and pre-cancerous geriatric skin conditions.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).